FOLH1 and prostate carcinoma: PSMA-targeted RLT is reshaping the treatment landscape for prostate cancer, expanding treatment options for patients with advanced prostate cancer and contributing to improved outcomes and quality of life, both in clinical trials and in routine practice [37].